

A NEW CLASS OF PENEMS
—C(2)-N-SUBSTITUTED COMPOUNDS—
SYNTHESIS AND ANTIBACTERIAL
ACTIVITY

Sir:

Penems are a novel class of highly active β -lactam antibiotics, extensively investigated for the past ten years. From a structure and activity point of view, presence of a hydroxyethyl substituent (6*S*,8*R*) at C(6) is well recognized to be beneficial for the β -lactamase stability and broad-spectrum activity of penems¹⁻³⁾ and carbapenems⁴⁾. A variety of substituents bearing a sulfur, carbon or oxygen at C(2) have been synthesized and their effect on the antimicrobial activity is readily available in the literature^{5,6-7)}. There is, however, little information forthcoming on the C(2)-nitrogen substituted penems. Here, we wish to report the synthesis and biological activities of C(2)-nitrogen linked penems.

Two types of compounds have been investigated in our laboratories, viz C(2)-mono-*N*-alkyl penems and C(2)-*N*-heterocyclic penems. The former was synthesized by employing a combination of previously reported procedures^{8,9)}, Scheme 1.

The β -lactam thiol (2), obtained by treating the silver salt⁹⁾ (1) with H₂S, was reacted with dibromo-*N*-ethylketimine⁸⁾ in methylene chloride in the presence of triethylamine to afford the penam (3) (50% after HPLC). The allyl, 2-

trimethylsilyl ethyl mixed esters are diastereomeric at C(3) and complicates the NMR data, the salient features of which are very similar to the di-trimethylsilyl ethyl ester. For simplicity the spectral data of the latter is given: NMR (CDCl₃) δ 5.35 (1H, d, $J=1.5$ Hz), 4.2~4.5 (5H, m), 3.5 (1H, dd, $J=1.5, 6$ Hz), 3.4 (2H, q), 1.15~1.45 (6H), 0.95 (9H, s), 0.1~0.05 (6H, 2s); FAB-MS m/z 617 (M+1)⁺ (base peak). Treatment of (3) with tetrabutyl ammonium fluoride in THF effected the cleavage of both the silyl protecting groups with concomitant loss of CO₂ yielding the penem/penam allyl ester (4, 5). Inseparable enamine-imine (1:1) mixture resulted in split peaks: salient peaks in the NMR (CDCl₃) δ 5.9 (1H, m), 5.4~5.5 (2d, $J=1.5, 2$ Hz, C(5)-H), 5.1~5.4 (2H, m), 4.6 (2H, m), 4.25 (1H, m), 3.5 (1H, dd, split), 3.45 (2H, m, split), 1.35 (3H, d, $J=8$ Hz), 1.2 (3H, t, split); FAB-MS m/z 299 (M+1)⁺ (base peak). Deblocking the allyl group¹⁰⁾ using Pd⁰ in the presence of sodium 2-ethyl hexanoate afforded the penem/penam sodium salt (6, 7) (the free acid was found to decarboxylate spontaneously when 2-ethyl hexanoic acid was used): NMR (D₂O) δ 5.5 (1H, d, $J=1.5$ Hz), 4.4 (1H, m), 3.65 (1H, dd, $J=1.5, 8$ Hz), 3.4 (2H, q, br), 1.1~1.45 (6H); FAB-MS m/z 281 (M+1)⁺ + Na, 215 (M+1)⁺ - COONa.

The C(2)-*N*-heterocyclic penems were made by the outlined general procedure in Scheme 2, exemplified by a 2-imidazol-1-yl penem. Reaction of the silver thiolate¹¹⁾ (8) with an appropriate

Scheme 1.









Table 1. *In vitro* antibacterial activity of selected penems.


Compound	Geometric mean MICs ($\mu\text{g/ml}$)*										
	<i>Bacillus</i>	<i>Escherichia coli</i>	<i>Enterobacter</i>	<i>Klebsiella</i>	<i>Morganella</i>	<i>Providencia</i>	<i>Salmonella</i>	<i>Micrococcus</i>	<i>Serratia</i>	<i>Staphylococcus</i>	<i>Enterococcus faecalis</i>
12a	0.12 (1)	0.94 (11)	2.5 (3)	1.1 (10)	4.0 (1)	3.0 (5)	0.63 (3)	0.12 (1)	6.7 (4)	0.21 (18)	4.0 (2)
12b	0.50 (1)	1.9 (11)	6.4 (3)	3.0 (10)	8.0 (1)	3.5 (5)	1.6 (3)	<0.02 (1)	16.0 (4)	0.30 (18)	5.7 (2)
12c	0.12 (1)	1.4 (11)	5.0 (3)	1.4 (10)	8.0 (1)	8.0 (5)	1.6 (3)	—	13.4 (4)	0.27 (17)	8.0 (2)
12d	0.06 (1)	0.94 (11)	5.0 (3)	1.1 (10)	8.0 (1)	4.6 (5)	1.6 (3)	—	9.5 (4)	0.06 (17)	2.8 (2)
12e	2.0 (1)	11.0 (11)	20.2 (3)	13.0 (10)	32.0 (1)	18.4 (5)	8.0 (3)	0.50 (1)	45.3 (4)	0.96 (18)	32.0 (2)
12f	0.06 (1)	0.68 (11)	3.2 (3)	0.81 (10)	2.0 (1)	2.3 (5)	0.50 (3)	—	5.7 (4)	0.12 (18)	5.7 (2)
12g	0.06 (1)	0.30 (11)	1.3 (3)	0.35 (10)	2.0 (1)	0.87 (5)	0.25 (3)	0.06 (1)	4.8 (4)	0.11 (18)	5.7 (2)

The figures in the parentheses indicate the number of strains examined.



* Mueller-Hinton agar, 24 hours.

**12a ~ g**


CH₂OH (4 or 5)



CH₃ (4 or 5)



Scheme 2.



thiocarbonyl bis-heterocycle afforded the di-thiocarbamate (9), which upon thermal cyclization yielded an isomeric mixture of *cis/trans* penems (10) and (11). The undesired *cis* isomer could be thermally isomerized^{12,13} to the biologically active *trans* series.

Finally, Pd⁰ catalyzed deblocking of the allyl protecting group¹⁰ provided the corresponding penem carboxylates (12a~e) in good yield. **12a**: NMR (D₂O) δ 8.85 (1H, br s), 7.57 (1H, br s), 7.4 (1H, br s), 5.8 (1H, d, $J=1.5$ Hz), 3.8 (1H, dd, $J=1.5, 8$ Hz), 1.25 (3H, d, $J=8$ Hz); FAB-MS m/z 282 (M+1)⁺.

Whereas the mono *N*-alkyl penem (7) turned out to be inactive in our tests (presumably due to the imine form, as well as decomposition under the test conditions), the *N*-heterocyclic penems (12a~e) were potent broad-spectrum antibiotics as compared to the activities of reference compounds FCE 22101 (12f) and Sch 34343 (12g) as shown in the Table 1.

The authors wish to thank Dr. B. PRAMANIK for the FAB-MS data.

VIYYOOR M. GIRIJAVALLABHAN*
 ASHIT K. GANGULY
 YI-TSUNG LIU
 PATRICK A. PINTO
 NAGINBHAI PATEL
 ROBERTA H. HARE
 GEORGE H. MILLER

Schering Research
 60 Orange Street,
 Bloomfield, N.J. 07003,
 U.S.A.

(Received March 24, 1986)

References

- 1) PHILLIPS, I.; R. WISE & H. C. NEU (Ed.): An oral penem antibiotic; Sch 29482. *J. Antimicrob. Chemother.* 9 Suppl. C: 1~243, 1982
- 2) UEDA, Y.; A. MARTEL, J.-P. DARIS, B. BELLEAU & M. MÉNARD: Nuclear analogs of β -lactam antibiotics. XV. Synthesis of 6-substituted 2-methylpenem-3-carboxylic acids. *Can. J. Chem.* 60: 904~909, 1982
- 3) OIDA, S.: Penems, synthetic approach to thienamycin analogues. *In Recent Advances in the Chemistry of β -Lactam Antibiotics*. Ed., G. I. GREGORY, pp. 330~348, The Royal Society of Chemistry, London, 1980
- 4) LEANZA, W. J.; K. J. WILDONGER, J. HANNAH, D. H. SHIH, R. W. RATCLIFFE, L. BARASH, E. WALTON, R. A. FIRESTONE, G. F. PATEL, F. M. KAHAN, J. S. KAHAN & B. G. CHRISTENSEN: Structure-activity relationships in the thienamycin series. *In Recent Advances in the Chemistry of β -Lactam Antibiotics*. Ed., G. I. GREGORY, pp. 240~254, The Royal Society of Chemistry, London, 1980
- 5) AFONSO, A.; A. K. GANGULY, V. GIRIJAVALLABHAN & S. MCCOMBIE: Synthesis of penem antibiotics. *In Recent Advances in the Chemistry of β -Lactam Antibiotics*. Eds., A. G. BROWN & S. M. ROBERTS, pp. 266~279, The Royal Society of Chemistry, London, 1984
- 6) COOKE, M. B.; K. W. MOORE, B. C. ROSS & S. E. TURNER: Synthesis and some antibacterial properties of 2-oxypenems. *In Recent Advances in the Chemistry of β -Lactam Antibiotics*. Eds., A. G. BROWN & S. M. ROBERTS, pp. 100~115, The Royal Society of Chemistry, London, 1984
- 7) FRANCESCHI, G.; M. ALPEGIANI, A. BADESCHI, M. FOGGIO, E. PERRONE, G. MEINARDI, S. GRASSO & I. DE CARNERI: A new class of

- penems, 2-heterocyclyl(thio)methyl derivatives. *J. Antibiotics* 37: 685~688, 1984 and cited references.
- 8) COSSEMENT, M.; J. MARCHAND-BRYNAERT, S. BOGDAN & L. GHOSEZ: A general route toward 2-oxo-, 2-thioxo- and 2-iminopenams and their conversion into 2-alkoxy-, 2-alkylthio- and 2-aminopenams. *Tetrahedron Lett.* 24: 2563~2566, 1983
 - 9) GIRIJAVALLABHAN, V. M.; A. K. GANGULY, P. PINTO & R. VERSACE: Synthesis of optically active penems-II. *Tetrahedron Lett.* 24: 3179~3182, 1983
 - 10) JEFFREY, P. D. & S. W. MCCOMBIE: Homogeneous palladium (O)-catalyzed exchange deprotection of allylic esters, carbonates, and carbamates. *J. Org. Chem.* 47: 587~590, 1982
 - 11) MARTEL, A.; P. DEXBAZE, J. P. DARIS, R. SAINTONGE, P. LAPOINTE, T. N. CONWAY, I. MONKOVIC, G. KAVADIAS, Y. UEDA, P. ELIE, S. PATEL, G. CARON, J. DOUGLAS, M. MENARD & B. BELLEAU: Nuclear analogs of beta-lactam antibiotics XIV. *Can. J. Chem.* 60: 942~944, 1982
 - 12) GIRIJAVALLABHAN, V. M.; A. K. GANGULY, S. W. MCCOMBIE, P. PINTO & R. RIZVI: Synthesis of optically active penems. *Tetrahedron Lett.* 22: 3485~3488, 1981
 - 13) HAYASHI, T.; A. YOSHIDA, N. TAKEDA, S. OIDA, S. SUGIWARA & E. OHKI: 2-(Alkylthio)penem-3-carboxylic acids. *Chem. Pharm. Bull.* 29: 3138~3172, 1981